Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

The fate of tumor-specific CD4(+) T cells is central to the outcome of the host immune response to cancer. We show that tumor antigen recognition by a subset of CD4(+) T cells led to their differentiation into cells capable of suppressing naive and Th1 effector cells. Such tumor-induced regulatory T cells (TMTregs) arose both from precommitted "natural" regulatory T cells and CD4(+)CD25(-)GITR(low) precursors. Once induced, TMTregs were capable of maintaining suppressor activity long after transfer into antigen-free recipients. Suppression was mediated by GITR(high) cells residing within both CD25(+) and CD25(-) subsets. Vaccination of the tumor-bearing host concomitantly expanded TMTregs and effector cells, but suppression was dominant, blunting the expansion of naive tumor-specific T cells and blocking the execution of effector function in vitro and in vivo. These studies illustrate the possibility that therapeutic vaccination could actually worsen host tolerance to tumor antigens and support treatment paradigms that seek to not only increase the frequency of tumor-specific T cells, but to do so in conjunction with strategies that inactivate or remove regulatory T-cell populations.

[1]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[2]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[3]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  H. Levitsky,et al.  Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression , 2004, The Journal of experimental medicine.

[5]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[6]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[7]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[8]  Polly Matzinger,et al.  'Educated' dendritic cells act as messengers from memory to naive T helper cells , 2004, Nature Immunology.

[9]  D. Pardoll,et al.  Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.

[10]  S. Sakaguchi,et al.  Development and function of CD25+CD4+ regulatory T cells. , 2004, Current opinion in immunology.

[11]  S. Sakaguchi.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.

[12]  P. Greenberg,et al.  Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. , 2004, Immunity.

[13]  E. Shevach,et al.  Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.

[14]  A. Cuenca,et al.  Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. , 2003, Cancer research.

[15]  Anna Chodos,et al.  Antigen-dependent Proliferation of CD4+ CD25+ Regulatory T Cells In Vivo , 2003, The Journal of experimental medicine.

[16]  L. Klein,et al.  In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[18]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[19]  A. Gallimore,et al.  CD25+ regulatory T cells and tumor immunity. , 2003, Immunology letters.

[20]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[21]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[22]  H. Waldmann,et al.  Dominant transplantation tolerance impairs CD8+ T cell function but not expansion , 2002, Nature Immunology.

[23]  T. Elliott,et al.  Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens , 2002, European journal of immunology.

[24]  B. Rocha,et al.  A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory , 2002, Science.

[25]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[26]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[27]  L. Klein,et al.  Origin of regulatory T cells with known specificity for antigen , 2002, Nature Immunology.

[28]  N. Restifo,et al.  Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? , 2002, Journal of immunotherapy.

[29]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[30]  V. Cerundolo,et al.  Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. , 2002, Cancer immunity.

[31]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[32]  F. Powrie,et al.  Regulatory T cells in the control of immune pathology , 2001, Nature Immunology.

[33]  A. Cuenca,et al.  Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. , 2001, Blood.

[34]  M. Roncarolo,et al.  Type 1 T regulatory cells , 2001, Immunological reviews.

[35]  H. Weiner,et al.  Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells , 2001, Immunological reviews.

[36]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[37]  M. Jordan.  Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide , 2001, Nature Immunology.

[38]  E. Shevach.  Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[39]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[40]  J. Allison,et al.  In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Bien,et al.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.

[42]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[44]  D. Longo,et al.  Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. , 1996, Journal of immunology.

[45]  E. Sotomayor,et al.  Tolerance and cancer: a critical issue in tumor immunology. , 1996, Critical reviews in oncogenesis.

[46]  R. North,et al.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor , 1980, The Journal of experimental medicine.